
TMDX Stock Forecast & Price Target
TMDX Analyst Ratings
Bulls say
TransMedics Group is facing potential challenges due to rising operating costs and competition in the market, but their innovative Organ Care System (OCS) technology has the potential to greatly improve organ transplantation outcomes. Despite slower market growth and increased competition, TransMedics is expected to maintain adequate reimbursement and potentially gain a larger share in the OCS market. Surgeons have shown mixed views on the company's next-generation OCS and ELATE study, but remain generally optimistic about its potential. However, TransMedics will need to carefully manage expenses and address any concerns from surgeons to achieve success in the organ transplantation market.
Bears say
TransMedics Group is facing challenges in the organ transplant market but remains confident in the potential of their technology and upcoming catalysts. However, its financial performance has been impacted by acquisitions and it may face further challenges from CMS initiatives and competition in the OPO market. These factors, combined with a potential overestimation of potential revenue, contribute to a negative outlook on the company's stock.
This aggregate rating is based on analysts' research of Transmedics Group Inc and is not a guaranteed prediction by Public.com or investment advice.
TMDX Analyst Forecast & Price Prediction
Start investing in TMDX
Order type
Buy in
Order amount
Est. shares
0 shares